Daxor Corporation (NasdaqCM:DXR) has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc. on March 25, 2024. The total transaction value will be paid in monthly installments over two years from that point, with payments anticipated to be supported by the revenue from Glofil and cost-savings from in-house manufacture of BVA test kits. The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.59 USD | +2.46% | +2.46% | -0.10% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.10% | 45.08M | |
+13.79% | 9.73B | |
-0.70% | 5.53B | |
+5.79% | 5.15B | |
+24.26% | 4.87B | |
-10.26% | 4.74B | |
+18.88% | 4.52B | |
-0.88% | 3.91B | |
-0.16% | 3.74B | |
+3.91% | 3.43B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc.